OvarPrimary diseas |
||
|
AGO-OVAR 16 / VEG110655
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Download |
|
|
AGO-OVAR 15
An open-label, multicentre, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for first-line treatment of patients with epithelial ovarian cancer FIGO stages IIb - IV.
|
Download |
|
|
AGO-OVAR 11
A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
|
Download |
|
|
AGO-OVAR 10
A randomized, double blind, placebo controlled, multicenre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapie.
|
Download |
|
|
AGO-OVAR 9
A multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I – IV. |
Download |
|
|
|
||
Recurrent disease |
||
|
AGO-OVAR 2.15 AURELIA / MO22224
A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
|
Download |
|
|
AGO-OVAR 2.12
HECTOR (Hycamtin plus Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse)
|
Download |
|
|
AGO-OVAR 2.11
A randomized multicentre trial with SU11248 to evaluate dosage, schedule, tolerability, toxicity and effectiveness of al multitargeted receptor tyrosine kinase inhibitor monotherapie.
|
Download |
|
|
AGO-OVAR 2.10
Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody removab® (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients.
|
Download |
|
|
AGO-OVAR 2.9
A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months).
|
Download |
|
|
AGO-OVAR 2.7
Reinduktionstherapie mit Paclitaxel und Carboplatin plus Epoetin Alfa versus Reinduktionstherapie mit Paclitaxel und Carboplatin beim rezidivierenden platinsensiblen Ovarialkarzinom.
|
Download |
|
|
AGO-OVAR 2.3
Topotecan versus Treosulfan in der Rezidivtherapie von Patientinnen mit Ovarialkarzinom nach Platin-/Paclitaxelvorbehandlung. |
Download |
|
|
|
||
Uterus |
||
|
AGO GYN 4
A phase I open label dose escalation study of oral treatment with BIBF 1120 in combination with standard treatment of paclitaxel and carboplatin in patients with advanced gynaecological malignancies.
|
||
|
AGO GYN 5 Phase II trial
Efficacy and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors.
|
Download |
|
|
AGO GYN 6
Feasibility Study of Pazopanib in Combination With Chemo in Gyn Tumors.
|
Download |
|
|
AGO GYN 7
Einsatz der Kombinationschemotherapie PegLiposomales Doxorubicin (PLD) und Carboplatin bei gynäkologischen Sarkomen und gemischt-mesenchymalen Tumoren. |
Download |
|
|
|
||
|
Vulvar |
||
|
AGO-VOP.1 CaRE
Chemo and Radiotherapy in Epithelial Vulvar Cancer |
Download |
|
|
|
||
Clinical trials in surgical settings |
||
|
AGO-OVAR OP.2/DESKTOP II Validation of a score of predictive factors for complete resection in paltium-sensitive ovarian cancer.
|
Download |
|
|
AGO-OVAR OP.3/LION
The role of lymphadnectomy in advanced ovarian cancer. |
Download |
|
|
|
|
|